Calls for papers
-
University of Michigan spin-off NanoBio Corporation has received its second grant for vaccine development from the Bill and Melinda Gates Foundation. The new $6 million grant is for development of an intranasal vaccine for respiratory… Read more . . .
-
According to Pearl Therapeutics, a Phase 2b study has demonstrated that its PT003 glycopyrrolate/formoterol combination MDI provides superior bronchodilation compared to placebo, compared to its individual components, and compared to tiotropium. The trial involved patients… Read more . . .
-
GlaxoSmithKline has increased its share of Theravance, with which it is developing Relovair fluticasone/vilanterol COPD product, to approximately 19%. In addition, GSK is crediting a UK "patent box" proposal to encourage R&D investments with in… Read more . . .
-
Verona Pharma, which has been looking for a partner for its lead product RPL554, an inhaled phosphodiesterase 3 and phosphodiesterase 4 inhibitor for the treatment of asthma, COPD, and allergic rhinitis, announced that it has… Read more . . .
-
An article published in The Lancet on November 20, 2010 describes the case of a teen-aged boy who appeared to suffer from asthma exacerbations linked to emotional distress caused by his use of Facebook. His… Read more . . .
-
Researchers from the Medco Research Institute presented data at the 2010 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) showing that clinicians are prescribing ICS/LABA combination treatment for two thirds of… Read more . . .
-
Having recently announced that it stands by its clinical trials after a former executive filed suit against the company for retaliatory termination after he raised concerns about the validity of studies conducted in Russia and… Read more . . .
-
A Phase 3 study of the Qnaze beclamethasone nasal spray from Teva has demonstrated that the product produced significant symptom relief compared to placebo, according to a Teva presentation at the 2010 Annual Meeting of… Read more . . .
-
According to the European Medicines Agency, Schering-Plough Europe (Merck) has withdrawn its marketing authorization application for its Zenhale mometesone furoate/formoterol fumarate MDI. The company said that it was unable to provide data requested by the… Read more . . .
-
Microdose Therapeutx will now be able to offer the Nexus6 SmartinhalerLive technology as an integral component of its electronic dry powder inhaler. The Nexus6 technology will allow the Microdose DPI to provide real-time reporting of… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK